%0 Journal Article
%A Bolsewig, Katharina
%A Willemse, Eline A J
%A Sánchez-Juan, Pascual
%A Rábano, Alberto
%A Martínez, Minerva
%A Doecke, James D
%A Bellomo, Giovanni
%A Vermunt, Lisa
%A Alcolea, Daniel
%A Halbgebauer, Steffen
%A In 't Veld, Sjors
%A Mattsson-Carlgren, Niklas
%A Veverova, Katerina
%A Fowler, Christopher J
%A Boonkamp, Lynn
%A Koel-Simmelink, Marleen
%A Hussainali, Zulaiga
%A Ruiters, Daimy N
%A Gaetani, Lorenzo
%A Toja, Andrea
%A Fortea, Juan
%A Pijnenburg, Yolande
%A Lemstra, Afina W
%A van der Flier, Wiesje M
%A Hort, Jakub
%A Otto, Markus
%A Hansson, Oskar
%A Parnetti, Lucilla
%A Masters, Colin L
%A Lleó, Alberto
%A Teunissen, Charlotte E
%A Del Campo Milán, Marta
%T Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.
%J Nature Communications
%V 16
%N 1
%@ 2041-1723
%C [London]
%I Springer Nature
%M DZNE-2025-00286
%P 1139
%D 2025
%X DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
%K Humans
%K Lewy Body Disease: drug therapy
%K Lewy Body Disease: blood
%K Lewy Body Disease: cerebrospinal fluid
%K Dopa Decarboxylase: metabolism
%K Male
%K Female
%K Aged
%K Parkinson Disease: drug therapy
%K Parkinson Disease: blood
%K Parkinson Disease: cerebrospinal fluid
%K Biomarkers: blood
%K Biomarkers: cerebrospinal fluid
%K Aged, 80 and over
%K Middle Aged
%K Dopamine Agents: therapeutic use
%K Cohort Studies
%K Longitudinal Studies
%K Dopa Decarboxylase (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%K Dopamine Agents (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39881147
%R 10.1038/s41467-025-56293-z
%U https://pub.dzne.de/record/276323